We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Expert Opinion / Interview · July 30, 2018

Durvalumab as Late Stage Treatment of NSCLC: Relationship With EGFR, ALK and PD-L1 Positivity—A West Cancer Center Perspective

Interview with
David C Portnoy MD
Interview questions written by
Erin Schenk MD, PhD


Further Reading